Hexarelin is the most potent synthetic growth hormone releasing peptide (GHRP) studied to date. Among all the GHRPs — GHRP-2, GHRP-6, ipamorelin, pralmorelin — hexarelin produces the largest GH pulses per dose in both animal and human studies. But what makes hexarelin particularly scientifically interesting is its dual mechanism: beyond GH secretion through GHSR, it also activates CD36 receptors directly in cardiac and other tissues, producing GH-independent anabolic and cardioprotective effects.
What Is Hexarelin?
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide GH secretagogue that was developed as an optimized GHRH mimetic through systematic structure-activity studies of GHRP-6 derivatives. It is the most potent GHRP in the classic series, surpassing GHRP-2, GHRP-6, and ipamorelin in GH-stimulating potency.
Dual Mechanisms of Action
GHSR-1a Activation (GH Release)
Like all GHRPs, hexarelin activates the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus, triggering potent GH release. Hexarelin’s GH pulse magnitude exceeds that of other GHRPs at comparable doses — making it the reference compound for maximum GH stimulation in secretagogue research.
CD36 Receptor Activation (GH-Independent)
This is hexarelin’s most distinctive and scientifically novel feature: it activates CD36 (SR-B2) receptors in cardiac muscle, adrenal cortex, and other tissues — independently of GHSR and GH secretion. CD36 is a multifunctional scavenger receptor involved in fatty acid uptake, angiogenesis, and anti-inflammatory signaling. Hexarelin’s CD36 activation produces direct cardioprotective effects, stimulates IGF-1 production in cardiac tissue, and activates Akt signaling — all independent of GH release.
Key Research Findings
Maximum GH Stimulation
Human studies confirm hexarelin produces GH pulses substantially larger than GHRP-2, GHRP-6, or ipamorelin at equivalent doses. Combined with GHRH or CJC-1295, the synergistic GH release is among the highest achievable with any secretagogue combination.
Cardiac Protection
In ischemia-reperfusion cardiac models, hexarelin treatment reduces infarct size, preserves left ventricular function, and promotes cardiac recovery — through CD36-mediated mechanisms independent of GH. This direct cardioprotective activity distinguishes hexarelin from other GHRPs and has generated significant research interest in cardiac biology.
Cortisol and Prolactin
Unlike ipamorelin, hexarelin does elevate cortisol and prolactin alongside GH — consistent with less receptor selectivity. These off-target effects are dose-dependent and are an important consideration in research protocol design comparing hexarelin to more selective GHRPs like ipamorelin.
Hexarelin vs. Other GHRPs
| Peptide | GH Potency | Cortisol Elevation | Unique Feature |
|---|---|---|---|
| Hexarelin | Highest | Significant | CD36 cardioprotection |
| GHRP-2 | High | Significant | Potent, well-studied |
| GHRP-6 | High | Significant | Strong appetite stimulation |
| Ipamorelin | High | Minimal | Clean selectivity profile |
Conclusion
Hexarelin’s combination of maximum GH-stimulating potency and unique CD36-mediated cardioprotective activity makes it a scientifically distinctive research compound. For researchers studying GH secretagogue biology, cardiac protection, or investigating CD36 receptor pharmacology, hexarelin offers capabilities no other GHRP can match. Combat Research carries research-grade hexarelin for qualified research applications.
Shop Hexarelin at Combat Research
Related Research Articles
For research purposes only. Not for human therapeutic use.
